Back to search

Institutes outside Greece

Deciphering the molecular responses of the striatal medium spiny neuron (MSN) subpopulations upon chronic moderate dopamine depletion and L-DOPA application in a rAAV-alpha-Synuclein mouse model

Abstract

dc:description

Parkinson's disease (PD) is an age-related neurodegenerative disorder, worldwide affecting million of people with an upward trend in the next decades. PD hallmarks include the degeneration of the nigrostriatal dopaminergic neurons in the substantia nigra pars compacta, and the intraneuronal accumulation of aggregated alpha-Synuclein. PD patients, upon dopamine deficiency in the basal ganglia circuitry, develop cardinal motor dysfunctions accompanied with early-onset and late-stage non-motor symptoms. Genetic and environmental factors contribute significantly to neurodegeneration, yet a comprehensive etiology of PD still remains elusive. The majority of PD cases are sporadic, modified by gene-environmental interactions, while the familial PD only represents a 5%-10% of the total cases. The pathophysiology underlying PD encompasses manifold molecular and cellular mechanisms, however, it is not entirely understood. Gene mutations, protein clearance machinery deficits, mitophagy deficits, oxidative stress and neuroinflammation are regarded the top culprits leading to alpha-Synuclein aggregation and pathology. While the aggregated alpha-Synuclein propagates throughout the brain, dopaminergic neuronal somata and nigrostriatal fibers are primarily susceptible to degeneration and cell death. Dopaminergic nigrostriatal fibers provide the striatum, a major nucleus of basal ganglia, with the neurotransmitter dopamine, regulating the motor pathways. Dopamine deficiency can disturb the imbalance between „direct“ and „indirect“ motor pathways resulting in PD motor symptoms. No curative therapies to prevent disease progression are yet available, and all pharmacological interventions aim to PD symptoms alleviation. To date, L-DOPA remains the gold standard among the dopaminergic therapeutic applications for motor symptoms management in PD. However, dopamine substitution is not always satisfactory in the long run, when PD patients often develop motor fluctuations and L-DOPA-induced dyskinesias (LID). Nevertheless, in early stages of PD upon L-DOPA application, patients enjoy a „honeymoon period“, and they display a long duration response (LDR) that requires weeks to build up and days to vanish without manifesting motor fluctuations. LDR cannot be explained by drug kinetics, and it is postulated that the buffering capacity of LDR effect could involve adaptive homeostatic plastic synaptic alterations in the basal ganglia circuitry. In this study, I examined the synaptic plasticity-related molecular responses of different medium spiny neuron (MSN) subpopulations in mouse striatum upon a moderate dopamine depletion and chronic L-DOPA administration. Striatum is predominantly occupied by the MSN GABAergic neurons, which can be classified into two major subpopulations, D1-MSNs and D2-MSNs, mainly based on their D1 and D2 dopamine receptor expression, respectively. D1 dopamine receptor stimulation activates downstream signaling cascades that positively regulates the „direct“ motor pathway through D1-MSN potentiation. In contrast, D2 dopamine receptor stimulation exerts inhibitory downstream signaling suppressing D2-MSN activity, and eventually the „indirect“ pathway, promoting normal mobility. Dopamine depletion and substitution can modulate the activity of MSN striatal neurons leading to motor pathways deregulation and motor deficits. D1 and D2 dopamine receptor downstream cascades are tightly linked to signaling pathways, such as cAMP, calcium and MAPK-ERK1/2 pathways, which regulate the synaptic plasticity in MSNs. These pathways, upon abnormal dopamine levels in striatum can establish synaptic plastic changes shaping the excitation status of MSN neurons. MSN populations are highly heterogeneous, and they can be subclustered further into subpopulations with discrete gene profiles and distinct molecular responses upon dopamine depletion and substitution. So far, most scientific evidence, about the molecular responses in striatum, are derived from animal models with extensive dopaminergic loss, displaying Abnormal Involuntary Movements (AIM) after L-DOPA administration (LID animal models). However, little is known about the molecular signaling responses, the homeostatic compensatory mechanisms and the synaptic plastic adaptations that are established in MSN subpopulations upon a moderate dopamine depletion in mouse striatum, and chronic L-DOPA administration that does not elicit AIMs. Herewith, in order to establish a mouse model with a moderate dopamine depletion in striatum, I injected the serotype 2/7 rAAV encoding human alpha-Synuclein A53T mutant, into the substantia nigra (SN). Human alpha-Synuclein ectopic overexpression in SN ensures a progressive and moderate dopaminergic neurodegeneration in both SN and striatum. Moreover, A53T mutant can enhance the protein aggregation resulting in early parkinsonism. Indeed, alpha-Synuclein overexpression by means of rAAV vector led to a partial dopaminergic degeneration in SN, and elicited mild asymmetry of forelimb use in a cylinder test. Furthermore, dopamine depleted mice underwent AIM recordings without scoring dyskinetic phenotypes. Then, by employing enzymatic dissociation protocol, FACS sorting and Single-cell transcriptomic analysis, I clustered the dorsal striatal neuronal and non-neuronal subpopulations. After unbiased Uniform Manifold Approximation and Projection (UMAP) clustering, I identified the major D1- and D2-MSN populations based on commonly known marker genes, and classified them into subclusters. D1-MSN subclusters displayed a big number of differentially expressed genes (DEGs), being consistent with previous studies. Strikingly, individual D1- and D2-MSN subclusters exhibited distinct sets of DEGs upon dopamine depletion and substitution, with unique upregulated and downregulated genes between comparisons, indicating the heterogeneity in terms of molecular responses among MSN subclusters. Several differentially expressed genes, especially in the D1-MSN subclusters, were associated with the cAMP-calcium-MAPK signaling pathway modulators and components. Dopamine depletion and substitution, by modulating the normal D1 and D2 receptor signaling, induced molecular responses that likely could establish synaptic maladaptive changes leading to aberrant MSN activity. Nevertheless, homeostatic compensatory molecular responses emerged possibly to counteract the deregulated signaling pathways in MSN subclusters, and consequently to restore their normal activity phenotype. These emerging homeostatic responses possibly explains the mild forelimb asymmetry upon dopamine depletion in this animal model, as well as the absence of AIMs after chronic L-DOPA administration. Finally, in this study I attempted to identify the striatal glial subpopulations, and to address the glial activation phenotypes upon different conditions. Conclusively, with this work, I established a mouse model that could be used to investigate the molecular signaling responses and homeostatic mechanisms among the different MSN subpopulations in early parkinsonism with a moderate dopamine deficiency, as well as the early stages of dyskinesia triggering.

Degree

thesis:*
Grantor dc:publisher
Institutes outside Greece
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kalliakoudas, Theodoros
  • Καλλιακούδας, Θεόδωρος

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58836

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kalliakoudas, Theodoros; Καλλιακούδας, Θεόδωρος. Deciphering the molecular responses of the striatal medium spiny neuron (MSN) subpopulations upon chronic moderate dopamine depletion and L-DOPA application in a rAAV-alpha-Synuclein mouse model. Institutes outside Greece, 2024. http://hdl.handle.net/10442/hedi/58836